Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

ClinicalTrials.gov ID: NCT00141661

Public ClinicalTrials.gov record NCT00141661. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

Study identification

NCT ID
NCT00141661
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
67 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2005 (Type not available)
Primary completion
Jun 2006 (Actual)
Completion
Jun 2006 (Actual)
Last update posted
Aug 20, 2009

2005 – 2006

United States locations

U.S. sites
12
U.S. states
4
U.S. cities
12
Facility City State ZIP Site status
Pfizer Investigational Site Sun City Arizona 85351 —
Pfizer Investigational Site Fresno California 93720 —
Pfizer Investigational Site San Diego California 92103 —
Pfizer Investigational Site San Francisco California 94118 —
Pfizer Investigational Site Fort Lauderdale Florida 33321 —
Pfizer Investigational Site Fort Myers Florida 33912 —
Pfizer Investigational Site Hallandale Florida 33009 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Largo Florida 33773 —
Pfizer Investigational Site Orlando Florida 32806 —
Pfizer Investigational Site West Palm Beach Florida 33407 —
Pfizer Investigational Site Memphis Tennessee 38119 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00141661, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2009 · Synced Oct 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00141661 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →